



Coproduction of MCR-1 and NDM-1 by Colistin-Resistant *Escherichia coli* Isolated from a Healthy Individual

Lan-Lan Zhong,^{a,b} Yan-Fen Zhang,^{a,b} Yohei Doi,^c Xi Huang,^{b,d} Xue-Fei Zhang,^{a,b} Kun-Jiao Zeng,^{a,b} Cong Shen,^{a,b} Sandip Patil,^{a,b} Yong Xing,^{a,b} Yutian Zou,^{a,b} Guo-Bao Tian^{a,b}

Program of Immunology, Institute of Tuberculosis Control, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China^a; Key Laboratory of Tropical Diseases Control (Sun Yat-sen University), Ministry of Education, Guangzhou, China^b; Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA^c; Program of Immunology, Institute of Human Virology, Affiliated Guangzhou Women and Children's Medical Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China^d

KEYWORDS *Escherichia coli*, *mcr-1*, *bla*_{NDM-1}

The first transferable plasmid-mediated colistin resistance gene, *mcr-1* was reported in *Escherichia coli* isolates from food animals, food, and patients in China and now has been reported worldwide (1). Furthermore, cocarriage of *mcr-1* and *bla*_{NDM} has been reported in *E. coli* and other members of the family *Enterobacteriaceae* from a chicken meat sample; patients with peritonitis, urinary tract infections, and rectal cancer; and a Muscovy duck, all in China. Most recently, *E. coli* carrying *mcr-1* and *bla*_{NDM-5} was isolated from a patient with a urinary tract infection in the United States (2–7). Here, we report asymptomatic carriage of *E. coli* harboring both *mcr-1* and *bla*_{NDM-1} in an otherwise healthy individual.

A total of 151 nonduplicate, serial fecal specimens were collected from 98 inpatients and 53 healthy individuals at Guangdong General Hospital in Guangzhou, China, during the first week of January 2016 for the purpose of detecting extended-spectrum β -lactamase-producing *Enterobacteriaceae*. Each sample was screened on a Columbia blood agar plate without any antibiotics and then subcultured on MacConkey agar with 2 μ g/ml cefotaxime. Colonies selected from the MacConkey agar were identified to the species level by the API 20E system (bioMérieux, Marcy l'Etoile, France) and 16S rRNA gene sequencing (8). As a result, 73 nonduplicate *E. coli* isolates were collected from 58 inpatients and 15 healthy individuals. Of these isolates, 17 were found to harbor *mcr-1* by PCR assay and sequencing performed as previously described (1, 8). Of the 17 *mcr-1*-carrying *E. coli* isolates, 2 were from clinical cultures of inpatients, 12 were from rectal surveillance cultures of inpatients, and 3 (*E. coli* GB049, GB090, and GB135) were from healthy individuals who provided rectal cultures with stool specimens after consent during outpatient visits for their annual physical examinations. Since carriage of *mcr-1* by healthy individuals is of particular epidemiologic interest, we analyzed these three strains further.

E. coli GB049 was recovered from a 23-year-old male, *E. coli* GB090 was from a 68-year-old female, and *E. coli* GB135 was from a 56-year-old female. These healthy individuals were all nonvegetarian, living in the city >10 km from commercial animal farms, drinking the municipal water, had received a secondary or tertiary education, had a mid to high socioeconomic status, and had traveled overseas. The individual with *E. coli* GB049 traveled in India for 5 days in September 2015; and the other two individuals with *E. coli* GB090 and GB135 traveled to the United States for 9 and 15 days, respectively, in December 2015. In addition, the individual with *E. coli* GB090 had taken oral amoxicillin for several days for her respiratory symptoms 3 months earlier.

Accepted manuscript posted online 7 November 2016

Citation Zhong L-L, Zhang Y-F, Doi Y, Huang X, Zhang X-F, Zeng K-J, Shen C, Patil S, Xing Y, Zou Y, Tian G-B. 2017. Coproduction of MCR-1 and NDM-1 by colistin-resistant *Escherichia coli* isolated from a healthy individual. *Antimicrob Agents Chemother* 61:e01962-16. <https://doi.org/10.1128/AAC.01962-16>.

Copyright © 2016 American Society for Microbiology. All Rights Reserved.

Address correspondence to Guo-Bao Tian, tiangb@mail.sysu.edu.cn.

TABLE 1 Characterization of three *mcr-1*-positive *E. coli* isolates from healthy individuals and their transconjugants

Parameter	<i>E. coli</i> GB049	Transconjugant of <i>E. coli</i> GB049	<i>E. coli</i> GB135	<i>E. coli</i> GB090	Transconjugant of <i>E. coli</i> GB090	<i>E. coli</i> EC600
Isolation date	1 January 2016		4 January 2016	2 January 2016		
Source	Healthy individual		Healthy individual	Healthy individual		
Isolation site	Feces		Feces	Feces		
MLST result	ST1193		ST38	ST744		
Phylogenetic group	D		D	B2		
Resistance gene(s) ^a	<i>mcr-1</i> , <i>bla</i> _{TEM-1}	<i>mcr-1</i> , <i>bla</i> _{TEM-1}	<i>mcr-1</i> , <i>bla</i> _{TEM-1}	<i>mcr-1</i> , <i>bla</i> _{NDM-1} , <i>bla</i> _{TEM-1} , <i>bla</i> _{SHV-12} , <i>bla</i> _{CTX-M-15} , <i>bla</i> _{CTX-M-14} , <i>fosA3</i> , <i>qnrB</i> , <i>qnrS</i> , <i>aac(6')-Ib-cr</i>	<i>mcr-1</i> , <i>bla</i> _{CTX-M-15} , <i>bla</i> _{TEM-1}	
Plasmid replicon type(s)	IncI2	IncI2	IncFIB, IncN	IncFI, IncN, IncP, IncK	IncFI	
MIC (μ g/ml) of:						
Colistin	8	16	16	16	16	0.25
Polymyxin B	16	16	16	16	16	0.5
Tigecycline	0.5	0.25	0.5	1	0.5	0.25
Ampicillin	>256	>256	>256	>256	>256	8
Amoxicillin-clavulanic acid	16	4	16	128	8	2
Cefotaxime	\leq 1	\leq 1	\leq 1	128	256	\leq 1
Ceftazidime	\leq 1	\leq 1	\leq 1	>256	64	\leq 1
Cefepime	\leq 0.5	\leq 0.5	\leq 0.5	16	32	\leq 0.5
Gentamicin	2	\leq 1	\leq 1	128	4	\leq 1
Amikacin	4	2	2	8	4	2
Ertapenem	0.125	\leq 0.063	0.125	4	0.125	\leq 0.063
Imipenem	0.125	\leq 0.063	\leq 0.063	1	0.25	0.125
Meropenem	\leq 0.063	\leq 0.063	\leq 0.063	1	0.125	\leq 0.063
Fosfomycin	16	\leq 8	\leq 8	>512	16	\leq 8
Nitrofurantoin	\leq 8	\leq 8	16	32	16	\leq 8
Ciprofloxacin	0.125	0.064	0.064	16	0.064	\leq 0.032

^aDetermined by PCR and sequencing.

Antimicrobial susceptibility testing was performed by the agar dilution method and interpreted according to the breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2016) for colistin, polymyxin B, and tigecycline and those of the Clinical and Laboratory Standards Institute (CLSI, 2015) for other antimicrobials. All three isolates were resistant to colistin and polymyxin B but susceptible to tigecycline and amikacin. In addition, *E. coli* GB090 was also resistant to cephalosporins, ertapenem, fosfomycin, and ciprofloxacin.

PCR was performed to identify β -lactamase, plasmid-mediated quinolone resistance, and 16S rRNA methyltransferase genes as described previously (9–11). Sanger sequencing of both strands of all PCR products was performed. As a result, in addition to *mcr-1*, *E. coli* GB090 was positive for *bla*_{NDM-1}, *bla*_{TEM-1}, *bla*_{SHV-12}, *bla*_{CTX-M-15}, *bla*_{CTX-M-14}, *fosA3*, *qnrB*, *qnrS*, and *aac(6')-Ib-cr*.

All three *mcr-1*-positive *E. coli* isolates from healthy individuals were subjected to pulsed-field gel electrophoresis (PFGE) as previously described (12, 13). The three isolates were clonally unrelated by PFGE (data not shown). *E. coli* GB090 was then subjected to phylogenetic typing and multilocus sequence typing (MLST) according to the protocol at <http://mlst.warwick.ac.uk/mlst/dbs/Ecoli> (9) and classified into phylogenetic group B2 and sequence type 744 (ST744), which belongs to the ST10 complex. *E. coli* B2 ST744 was also reported in *mcr-1*-carrying *E. coli* from a human bloodstream infection and imported chicken meat in Denmark (14). Phylogenetic group B2 ST10 complex strains, along with phylogenetic group B2 ST131 and ST405 strains, have been implicated as vehicles driving the international spread of *bla*_{CTX-M-15} (15).

Rifampin-resistant *E. coli* EC600 was used as the recipient for the conjugation and transformation experiments. The transconjugants or transformations were selected on lysogeny broth (LB) agar plates containing rifampin (500 μ g/ml) plus colistin (4 μ g/ml), cefotaxime (16 μ g/ml), ertapenem (2 and 4 μ g/ml), or fosfomycin (256 μ g/ml). As a result, colistin-resistant transconjugants containing *mcr-1*, *bla*_{CTX-M-15}, and *bla*_{TEM-1} were successfully obtained from plates containing either colistin or cefotaxime for *E. coli* GB090, which was positive for an IncFI replicon by PCR-based replicon typing (16) (Table 1). We could not obtain transconjugants or transformants containing *bla*_{NDM-1}. In order to determine the locations of the *mcr-1* and *bla*_{NDM} genes, DNA linearization of

E. coli GB090 with S1 nuclease, followed by PFGE and Southern hybridization using *mcr-1* and *bla*_{NDM} gene probes, was conducted as previously described (17). The results indicated that *mcr-1* was located on an ~33-kDa plasmid together with the β -lactamase genes *bla*_{CTX-M-15} and *bla*_{TEM-1}, whereas *bla*_{NDM} was not located on this plasmid (see Fig. S1 in the supplemental material). Taking the results together, we speculate that *bla*_{NDM-1} may be located on the chromosome of *E. coli* GB090. In addition, colistin-resistant transconjugants containing *mcr-1* were successfully obtained for *E. coli* GB049 but not *E. coli* GB135.

The genomic DNA of *E. coli* GB090 was extracted and digested with EcoRI and XbaI and then ligated to cloning vector pBC-SK(-). The ligation products were transferred to *E. coli* DH10B by electroporation and cultured on LB agar supplemented with chloramphenicol (30 μ g/ml) and colistin (4 μ g/ml) or ertapenem (2 and 4 μ g/ml), which yielded colistin- and ertapenem-resistant transformants, respectively. Sequencing of the recombinant plasmids carried by these *E. coli* transformants revealed ~6.1- and ~8.1-kb inserts containing the *mcr-1* and *bla*_{NDM-1} genes, respectively.

Sequence analysis of the ~6.1-kb genetic environment surrounding *mcr-1* revealed 100% identity with that of pHNSHP45 in our previous study (1), which was also similar to the sequence found in various *mcr-1*-carrying plasmids, with up to 99% identity with pA31-12 from *E. coli* strain A31-12 (accession no. KX034083), pAF23 from *E. coli* strain Af23 (KX032519), pSCS23 from *Salmonella enterica* strain SC23 (KU934209), and pABC149-MCR-1 from *E. coli* strain ABC149 (KX013538). The genetic environment surrounding *bla*_{NDM-1} was identical to that found in various *bla*_{NDM-1}-carrying plasmids in *Enterobacteriaceae* in China, including pKP04NDM (KU314941), pNDM-HN380 (JX104760), pKPN5047 (KC311431), and pNDM-SX04 (KC876051) in *K. pneumoniae*; pYE315203 (JX254913) and p112298-NDM (KP987216) in *Citrobacter freundii*; pNDM-HF727 in *Enterobacter cloacae* (KF976405); and a plasmid in *Raoultella planticola* (KF877335). These results indicate that the genetic structures of both *mcr-1* and *bla*_{NDM-1} have likely already spread to different species of *Enterobacteriaceae*.

Recovery of *mcr-1*- and *bla*_{NDM-1}-carrying *E. coli* from a healthy individual suggests that *Enterobacteriaceae* with extreme antimicrobial resistance may already circulate in the community in China. Our findings underline the importance of continuous microbiological and molecular surveillance with regard to further dissemination of *mcr-1* in the community. The high rate of *mcr-1*-carrying *E. coli* isolation from both hospitalized and nonhospitalized patients also suggests intestinal colonization as a key source in its dissemination.

Accession number(s). The nucleotide sequences obtained in this study were submitted to the GenBank database and assigned accession no. KX886345 and KX886346.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/AAC.01962-16>.

TEXT S1, PDF file, 0.1 MB.

ACKNOWLEDGMENTS

We sincerely thank the patients and healthy individuals who participated in this study for giving written consent for publication.

This work was supported by grants from the National Natural Science Foundation of China (81471988), the National Key Research and Development Program (2016YFC1200105), The 111 Project (B13037, B12003), the Natural Science Foundation of Guangdong (S2013010015810), the Science and Technology Planning Project of Guangdong (2016A020219002), Fundamental Research Funds for the Central Universities (16ykd09), and the Program of Science and Technology New Star of Guangzhou (2014J2200038).

Y.D. has served on an advisory board for Shionogi, Meiji, Tetrphase, and Achaogen; consulted for Melinta; and received research support from Merck and The Medicines Company for studies unrelated to this work. All of the other authors have no conflicts of interest to declare.

REFERENCES

- Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis* 16:161–168. [https://doi.org/10.1016/S1473-3099\(15\)00424-7](https://doi.org/10.1016/S1473-3099(15)00424-7).
- Yu H, Qu F, Shan B, Huang B, Jia W, Chen C, Li A, Miao M, Zhang X, Bao C, Xu Y, Chavda KD, Tang YW, Kreiswirth BN, Du H, Chen L. 2016. Detection of the *mcr-1* colistin resistance gene in carbapenem-resistant *Enterobacteriaceae* from different hospitals in China. *Antimicrob Agents Chemother* 60:5033–5035. <https://doi.org/10.1128/AAC.00440-16>.
- Yang RS, Feng Y, Lv XY, Duan JH, Chen J, Fang LX, Xia J, Liao XP, Sun J, Liu YH. 22 August 2016. Emergence of NDM-5 and MCR-1-producing *Escherichia coli* clone ST648 and ST156 from a single Muscovy duck (*Cairina moschata*). *Antimicrob Agents Chemother* <https://doi.org/10.1128/AAC.01365-16>.
- Teo JQ, Ong RT, Xia E, Koh TH, Khor CC, Lee SJ, Lim TP, Kwa AL. 2016. *mcr-1* in multidrug-resistant *bla*_{KPC-2} clinical *Enterobacteriaceae* isolates in Singapore. *Antimicrob Agents Chemother* 60:6435–6437. <https://doi.org/10.1128/AAC.00804-16>.
- Mediavilla JR, Patrawalla A, Chen L, Chavda KD, Mathema B, Vinnard C, Dever LL, Kreiswirth BN. 2016. Colistin- and carbapenem-resistant *Escherichia coli* harboring *mcr-1* and *bla*_{NDM-5} causing a complicated urinary tract infection in a patient from the United States. *mBio* 7:e01191-16. <https://doi.org/10.1128/mBio.01191-16>.
- Yao X, Doi Y, Zeng L, Lv L, Liu JH. 2016. Carbapenem-resistant and colistin-resistant *Escherichia coli* co-producing NDM-9 and MCR-1. *Lancet Infect Dis* 16:288–289. [https://doi.org/10.1016/S1473-3099\(16\)00057-8](https://doi.org/10.1016/S1473-3099(16)00057-8).
- Du H, Chen L, Tang YW, Kreiswirth BN. 2016. Emergence of the *mcr-1* colistin resistance gene in carbapenem-resistant *Enterobacteriaceae*. *Lancet Infect Dis* 16:287–288. [https://doi.org/10.1016/S1473-3099\(16\)00056-6](https://doi.org/10.1016/S1473-3099(16)00056-6).
- Ye H, Li Y, Li Z, Gao R, Zhang H, Wen R, Gao GF, Hu Q, Feng Y. 2016. Diversified *mcr-1*-harbouring plasmid reservoirs confer resistance to colistin in human gut microbiota. *mBio* 7:e00177. <https://doi.org/10.1128/mBio.00177-16>.
- Tian GB, Huang YM, Fang ZL, Qing Y, Zhang XF, Huang X. 2014. CTX-M-137, a hybrid of CTX-M-14-like and CTX-M-15-like beta-lactamases identified in an *Escherichia coli* clinical isolate. *J Antimicrob Chemother* 69:2081–2085. <https://doi.org/10.1093/jac/dku126>.
- Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009. Characterization of a new metallo-beta-lactamase gene, *bla*(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother* 53:5046–5054. <https://doi.org/10.1128/AAC.00774-09>.
- Hou J, Huang X, Deng Y, He L, Yang T, Zeng Z, Chen Z, Liu JH. 2012. Dissemination of the fosfomycin resistance gene *fosA3* with CTX-M beta-lactamase genes and *rmtB* carried on IncFII plasmids among *Escherichia coli* isolates from pets in China. *Antimicrob Agents Chemother* 56:2135–2138. <https://doi.org/10.1128/AAC.05104-11>.
- Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol* 33:2233–2239.
- Tian GB, Wang HN, Zhang AY, Zhang Y, Fan WQ, Xu CW, Zeng B, Guan ZB, Zou LK. 2012. Detection of clinically important beta-lactamases in commensal *Escherichia coli* of human and swine origin in western China. *J Med Microbiol* 61:233–238. <https://doi.org/10.1099/jmm.0.036806-0>.
- Hasman H, Hammerum AM, Hansen F, Hendriksen RS, Olesen B, Agerso Y, Zankari E, Leekitcharoenphon P, Stegger M, Kaas RS, Cavaco LM, Hansen DS, Aarestrup FM, Skov RL. 2015. Detection of *mcr-1* encoding plasmid-mediated colistin-resistant *Escherichia coli* isolates from human bloodstream infection and imported chicken meat, Denmark 2015. *Euro Surveill* 20(49):pii=30085. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21331>.
- Cantón R, Gonzalez-Alba JM, Galan JC. 2012. CTX-M enzymes: origin and diffusion. *Front Microbiol* 3:110. <https://doi.org/10.3389/fmicb.2012.00110>.
- Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 2005. Identification of plasmids by PCR-based replicon typing. *J Microbiol Methods* 63:219–228. <https://doi.org/10.1016/j.mimet.2005.03.018>.
- Sidjabat HE, Paterson DL, Adams-Haduch JM, Ewan L, Pasculle AW, Muto CA, Tian GB, Doi Y. 2009. Molecular epidemiology of CTX-M-producing *Escherichia coli* isolates at a tertiary medical center in western Pennsylvania. *Antimicrob Agents Chemother* 53:4733–4739. <https://doi.org/10.1128/AAC.00533-09>.